ACADIA Pharmaceuticals Inc. (ACAD) is a Healthcare stock trading at $21.61 (as of 2026-06-18), with a market capitalization of $3.67B and a trailing P/E of 9.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
ACADIA Pharmaceuticals Inc. develops and commercializes small-molecule therapies for central nervous system disorders. It markets NUPLAZID (pimavanserin) for hallucinations and delusions linked to Parkinson’s disease psychosis and has product candidates in clinical development for conditions including Alzheimer’s disease psychosis, Rett syndrome, and schizophrenia.